Germany, July 15, 2025 – Pharmatech AI has entered into a strategic collaboration with Deutsche Anbaugesellschaft DAG GmbH, marking a significant advancement in cannabinoid-based therapy development through artificial intelligence. This partnership combines Pharmatech AI’s cutting-edge AI technologies with DAG’s extensive expertise in cannabis cultivation and processing to create a powerful synergy in pharmaceutical research.
Through this collaboration, Pharmatech AI gains access to DAG’s comprehensive resources and specialized knowledge, including their well-established network within the European cannabis industry, practical experience in licensed cannabis cultivation, and deep understanding of regulatory processes and certification requirements. This access enables Pharmatech AI to enhance its proprietary AI-MDIP platform with valuable real-world data.
Ercan Hayvali, M.Sc., CEO of Pharmatech AI, emphasized the significance of this partnership: “By integrating DAG’s cultivation data with our existing database of 50,000 data points per research cycle, we can significantly improve the predictive accuracy of our AI-MDIP model. This enhanced capability allows us to accelerate our drug development processes and deliver more precise therapeutic solutions.”
The partnership provides Pharmatech AI with multiple strategic advantages. The improved data foundation supports more efficient development of novel drug compounds, while DAG’s regulatory expertise facilitates faster market entry for developed products. Additionally, the collaboration opens new possibilities for product development and innovation in cannabinoid-based therapies.
Martin Heine, Operations Manager at Deutsche Anbaugesellschaft DAG, commented on the partnership’s potential: “Working with Pharmatech AI allows us to contribute to groundbreaking advancements in our industry. Their AI-driven approach combined with our cultivation expertise creates exciting opportunities for developing innovative medical cannabis applications.”
The companies have already identified several joint projects, including the optimization of cannabinoid profiles for specific medical applications and the development of integrated solutions across the cannabis value chain. This partnership comes at a pivotal time as the European medical cannabis market continues to experience significant growth.
Strategic Importance of the Partnership
For Pharmatech AI, this collaboration represents a crucial step in strengthening its position in the global medical cannabis market. Germany’s stringent regulatory environment makes DAG’s local expertise particularly valuable, providing Pharmatech AI with not only high-quality cultivation data but also critical insights into compliance and quality standards.
The expanded data resources resulting from this partnership give Pharmatech AI a distinct competitive advantage. As the AI-MDIP platform processes this growing body of information, its predictive capabilities become increasingly refined, enabling faster development of targeted therapies. Beyond the immediate benefits in Germany, this collaboration also accelerates Pharmatech AI’s expansion into other European markets.
Expanding Natural Compound Research Capabilities
This partnership significantly enhances Pharmatech AI’s natural compound research program, particularly in the field of cannabinoids. By incorporating DAG’s extensive cannabis expertise, researchers gain direct access to comprehensive cannabinoid data that will inform and improve the AI-MDIP platform’s drug discovery processes.
While cannabinoid research represents a primary focus, Pharmatech AI continues to advance its work in complementary areas including nanomedicine and pain medication development. The company sees substantial potential for establishing additional strategic partnerships with research institutions specializing in nanotechnological medical applications, pharmacological facilities for expanding active compound research, clinical partners for patient-focused studies, and academic institutions to further strengthen its research network.
This multidisciplinary approach ensures Pharmatech AI maintains long-term competitive advantages while positioning itself as a comprehensive partner for innovative therapeutic development – from initial natural compound analysis through to clinical implementation.
About Deutsche Anbaugesellschaft DAG
Deutsche Anbaugesellschaft DAG GmbH (deutsche-anbaugesellschaft.de) stands as a leader in licensed cannabis cultivation across Europe. With years of operational experience, the company has developed extensive expertise in all aspects of cannabis production in Germany. DAG’s comprehensive portfolio enables it to address diverse market needs, encompassing both medical and recreational cannabis sectors.